Streamlining Anthem (Elevance Health) Biologics Prior Auth

Navigating the complexities of Anthem (Elevance Health) biologics prior auth is a critical challenge for revenue cycle teams. Klivira provides a purpose-built automation solution to expedite these high-volume, high-cost authorizations.

Biologic therapies, including TNF inhibitors, IL-17/23 inhibitors, and JAK inhibitors, represent a significant portion of specialty drug spend and frequently require prior authorization. For clinics, hospitals, and health systems, managing these authorizations for Anthem-licensed plans demands precise adherence to payer-specific criteria, submission channels, and policy nuances. Klivira's platform is engineered to integrate these requirements, transforming a historically manual and error-prone process into an efficient, automated workflow.

Anthem's Diverse Channels for Biologics Prior Auth Submission

Anthem-licensed plans, operating under Elevance Health, utilize multiple channels for prior authorization, depending on the benefit and drug administration. For medical-benefit biologics, submissions often route through Availity Essentials, Anthem's primary multi-payer provider workspace, which supports PA initiation and document upload. X12 278 transactions are also accepted via clearinghouses. Pharmacy-benefit biologics typically route through CarelonRx's provider PA system or through ePA partners like CoverMyMeds and Surescripts, requiring precise channel identification for each agent.

Klivira's Automated Workflow for Anthem Biologics

**Indication Classification:** Automatically identifies the specific specialty and disease state from EMR diagnoses, matching it to Anthem's indication-specific PA criteria.
**Step Therapy Automation:** Pulls prior-line therapy history (e.g., csDMARDs for rheumatology, 5-ASA for IBD) to satisfy Anthem's step therapy requirements.
**Biosimilar Substitution Routing:** Applies Anthem's per-payer biosimilar mandates, ensuring compliance with preferred product policies.
**Screening Documentation:** Extracts and attaches required screening documentation (e.g., TB, hepatitis B/C, immunization status) directly from FHIR-enabled EMR data.
**Medical vs. Pharmacy Benefit Routing:** Intelligently routes the PA request to the correct Anthem channel based on the biologic agent and its administration mode, accommodating benefit-side distinctions.

Navigating Anthem's Biologics Policy and Utilization Management Criteria

Anthem operating companies maintain extensive medical-policy and clinical-UM-guideline libraries accessible via provider sites through Availity. These policies are state-specific for commercial, Medicare Advantage, and Medicaid plans, often referencing criteria from Anthem-developed, Carelon-developed, MCG, or NCCN compendium sources. Klivira's platform ensures that submitted documentation aligns with the precise policy number, plan-state context, and effective date, minimizing discrepancies that lead to delays or denials.

Addressing Turnaround Times and Common Denials for Anthem Biologics

Anthem-licensed plans' PA turnaround times are governed by state-mandated minimums for commercial lines, with material variance across states. For Medicare Advantage and Medicaid managed-care plans, CMS-0057-F mandates 72-hour standard and 24-hour expedited decision timeframes. Common denial categories for biologics include medical necessity (insufficient documentation), failure to complete step therapy, and site-of-service mismatches. Klivira's proactive validation and comprehensive submission package are designed to mitigate these frequent denial patterns, accelerating the path to approval.

Anthem's Electronic PA Posture and Data Exchange

Elevance Health, through its Anthem operating companies, has participated in Da Vinci Project initiatives and HL7 connectathons, indicating a commitment to electronic data exchange. Beyond X12 278 support, Anthem's retail pharmacy benefit leverages ePA partners like CoverMyMeds and Surescripts. Klivira integrates with these electronic pathways, facilitating structured data submission and status updates, reducing reliance on manual portal interactions and fax-based workflows.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit split for Anthem biologics?

Klivira's platform intelligently identifies whether a specific biologic agent falls under Anthem's medical or pharmacy benefit based on administration mode and payer rules. It then routes the prior authorization request to the appropriate channel, whether it's Availity for medical benefit or CarelonRx/ePA partners for pharmacy benefit, ensuring accurate submission.

What are the common reasons for Anthem biologics prior authorization denials?

Common denial reasons for Anthem biologics prior authorizations include insufficient documentation for medical necessity, failure to complete required step therapy, site-of-service mismatches (given active Carelon site-of-care policies), and non-formulary pharmacy denials. Klivira helps address these by ensuring comprehensive data submission and adherence to payer policies.

Where can I find Anthem's medical policies for biologics?

Anthem operating companies publish their medical policies and clinical utilization management guidelines through provider sites, typically accessed via Availity. It's crucial to reference the specific policy number, plan-state context, and effective date, as policies can vary by state and line of business.

Does Anthem (Elevance Health) support electronic PA for biologics?

Yes, Anthem supports electronic prior authorization through various channels. This includes X12 278 transactions for medical benefit PAs, and ePA partners like CoverMyMeds and Surescripts for pharmacy benefit PAs. Elevance Health has also participated in Da Vinci Project initiatives, indicating engagement with FHIR-based electronic PA standards.

How does Klivira ensure compliance with Anthem's step therapy requirements for biologics?

Klivira automates the validation of Anthem's step therapy requirements by pulling prior-line therapy history from the EMR. For example, it confirms completion of csDMARDs for rheumatology indications or 5-ASA for IBD, ensuring that the submitted PA request meets Anthem's clinical pathways before submission.